Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $140.43.
ASND has been the subject of several recent analyst reports. StockNews.com downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. Morgan Stanley upped their price target on Ascendis Pharma A/S from $113.00 to $116.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Wells Fargo & Company decreased their price target on Ascendis Pharma A/S from $139.00 to $134.00 and set an “overweight” rating for the company in a research note on Wednesday, September 6th. Wedbush reiterated an “outperform” rating and set a $192.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, November 8th. Finally, Bank of America increased their target price on Ascendis Pharma A/S from $107.00 to $113.00 in a research note on Thursday, September 7th.
Institutional Inflows and Outflows
Ascendis Pharma A/S Stock Performance
Shares of ASND stock opened at $89.43 on Friday. Ascendis Pharma A/S has a 1-year low of $64.33 and a 1-year high of $127.77. The company has a current ratio of 3.44, a quick ratio of 2.56 and a debt-to-equity ratio of 7.39. The company has a market capitalization of $5.16 billion, a price-to-earnings ratio of -7.87 and a beta of 0.48. The stock’s fifty day simple moving average is $93.81 and its 200-day simple moving average is $92.02.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its quarterly earnings data on Tuesday, September 5th. The biotechnology company reported ($2.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.33. The firm had revenue of $51.59 million during the quarter, compared to analysts’ expectations of $41.73 million. Ascendis Pharma A/S had a negative return on equity of 570.61% and a negative net margin of 391.76%. On average, sell-side analysts predict that Ascendis Pharma A/S will post -9.87 earnings per share for the current fiscal year.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.
- Five stocks we like better than Ascendis Pharma A/S
- How to Invest in Energy
- Catch the dip on Sociedad Quimica before earnings?
- How to Invest in Biotech Stocks
- Can new GPT store spur generative AI monetization?
- How is Compound Interest Calculated?
- Energy looks to dominate markets with 3 oil and gas stocks
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.